Annual report pursuant to Section 13 and 15(d)

BALANCE SHEETS

v3.6.0.2
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 14,006 $ 7,857
Receivables 3,587 4,213
Prepaid expenses and other current assets 237 174
Total current assets 17,830 12,244
Property and equipment, net 837 1,043
Total Assets 18,667 13,287
Current liabilities:    
Accounts payable 3,015 4,158
Accrued clinical trials expenses 1,387 341
Other accrued liabilities 455 354
Total current liabilities 4,857 4,853
Warrant liability 619 1,444
Total Liabilities 5,476 6,297
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued and outstanding at December 31, 2016 and 2015. 0 0
Common stock, at amounts paid-in, $0.001 par value per share; 125,000,000 shares authorized, 21,198,879 and 20,059,820 shares issued and outstanding at December 31, 2016 and 2015, respectively. 297,855 297,828
Additional paid-in capital 24,300 23,261
Accumulated deficit (308,964) (314,099)
Total stockholders’ equity 13,191 6,990
Total Liabilities and Stockholders’ Equity $ 18,667 $ 13,287